During his 26 years as a litigator and trial lawyer, Mr. Enright has handled matters in the fields of securities, commodities, consumer fraud and commercial litigation, with a particular emphasis on shareholder M&A and securities fraud class action litigation. He has been named as one of the leading financial litigators in the nation by Lawdragon, as a Washington, DC "Super Lawyer" by Thomson Reuters, and as one of the city's "Top Lawyers" by
Washingtonian magazine.
Mr. Enright has shown a track record of achieving victories in federal trials and appeals, including:
- Nathenson v. Zonagen, Inc., 267 F. 3d 400, 413 (5th Cir. 2001)
- SEC v. Butler, 2005 U.S. Dist. LEXIS 7194 (W.D. Pa. April 18, 2005)
- Belizan v. Hershon, 434 F. 3d 579 (D.C. Cir. 2006)
- Rensel v. Centra Tech Inc., 2 F. 4th 1359 (11th Cir. 2021)
Most recently, in
In re Schuff International, Inc. Stockholders Litigation, Case No. 10323-VCZ, Mr. Enright served as Co-Lead Counsel for the plaintiff class in achieving the largest recovery as a percentage of the underlying transaction consideration in Delaware Chancery Court merger class action history, obtaining an aggregate recovery of more than $22 million -- a gross increase from $31.50 to $67.45 in total consideration per share (a 114% increase) for tendering stockholders.
Similarly, as Co-Lead Counsel in
In re Bluegreen Corp. Shareholder Litigation, Case No. 502011CA018111 (Cir. Ct. for Palm Beach Cnty., Fla.), Mr. Enright achieved a $36.5 million common fund settlement in the wake of a majority shareholder buyout, representing a 25% increase in total consideration to the minority stockholders. Also, in
In re CNX Gas Corp. Shareholders Litigation, C.A. No. 53377-VCL (Del. Ch. 2010), in which Levi & Korsinsky served upon plaintiffs’ Executive Committee, Mr. Enright helped obtain the recovery of a common fund of over $42.7 million for stockholders.
Mr. Enright has also played a leadership role in numerous securities and shareholder class actions from inception to conclusion. Most recently, he has served as lead counsel in several cryptocurrency-related securities class actions. His leadership has produced multi-million-dollar recoveries in shareholder class actions involving such companies as:
- Allied Irish Banks PLC
- Iridium World Communications, Ltd.
- En Pointe Technologies, Inc.
- PriceSmart, Inc.
- Polk Audio, Inc.
- Meade Instruments Corp.
- Xicor, Inc.
- Streamlogic Corp.
- Interbank Funding Corp.
- Riggs National Corp.
- UTStarcom, Inc.
- Manugistics Group, Inc.
Mr. Enright also has a successful track record of obtaining injunctive relief in connection with shareholder M&A litigation, having won preliminary injunctions or other injunctive relief in the cases of:
- In re Portec Rail Products, Inc. S’holder Litig., G.D. 10-3547 (Ct. Com. Pleas Pa. 2010)
- In re Craftmade International, Inc. S’holder Litig., C.A. No. 6950-VCL (Del. Ch. 2011)
- Dias v. Purches, C.A. No. 7199-VCG (Del. Ch. 2012)
- In re Complete Genomics, Inc. S’holder Litig., C.A. No. 7888-VCL (Del. Ch. 2012)
- In re Integrated Silicon Solution, Inc. Stockholder Litig., Lead Case No. 115CV279142 (Sup. Ct. Santa Clara, CA 2015)
Mr. Enright has also demonstrated considerable success in obtaining deal price increases for shareholders in M&A litigation. As Co-Lead Counsel in the matter of
In re Great Wolf Resorts, Inc. Shareholder Litigation, C.A. No. 7328-VCN (Del. Ch. 2012), Mr. Enright was partially responsible for a $93 million (57%) increase in merger consideration and waiver of several “don’t-ask-don’t-waive” standstill agreements that were precluding certain potential bidders from making a topping bid for the company.
Similarly, Mr. Enright served as Co-Lead Counsel in the case of
Berger v. Life Sciences Research, Inc., No. SOM-C-12006-09 (NJ Sup. Ct. 2009), which caused a significant increase in the transaction price from $7.50 to $8.50 per share, representing additional consideration for shareholders of approximately $11.5 million.
Mr. Enright also served as Co-Lead Counsel in
Minerva Group, LP v. Keane, Index No. 800621/2013 (NY Sup. Ct. of Erie Cnty.) and obtained a settlement in which Defendants increased the price of an insider buyout from $8.40 to $9.25 per share.
The courts have consistently recognized and praised the quality of Mr. Enright’s work. In
In re Interbank Funding Corp. Securities Litigation, (D.D.C. 02-1490)
, Judge Bates of the United States District Court for the District of Columbia observed that Mr. Enright had “...skillfully, efficiently, and zealously represented the class, and... worked relentlessly throughout the course of the case.”
Similarly, in
Freeland v. Iridium World Communications, LTD, (D.D.C. 99-1002), Judge Nanette Laughrey stated that Mr. Enright had done “an outstanding job” in connection with the recovery of $43.1 million for the shareholder class.
And, in the matter of
Osieczanek v. Thomas Properties Group, C.A. No. 9029-VCG (Del. Ch. 2013), Vice Chancellor Sam Glasscock of the Chancery Court of Delaware observed that “it’s always a pleasure to have counsel [like Mr. Enright] who are articulate and exuberant in presenting their position,” and that Mr. Enright’s prosecution of a merger case was “wholesome” and served as “a model of . . . plaintiffs’ litigation in the merger arena.”
Education:
- George Washington University School of Law, J.D. (1996), Member Editor of The George Washington University Journal of International Law and Economics from 1994 to 1996
- Drew University, B.A. cum laude, Political Science and Economics (1993)
Admissions:
- Maryland (1996)
- New Jersey (1996)
- District of Maryland (1997)
- District of New Jersey (1997)
- Washington, DC (1999)
- United States District Court for the District of Columbia (1999)
- United States District Court for the District of Colorado (2017)
- United States Court of Appeals for the District of Columbia (2004)
- Second Circuit (2005)
- Third Circuit (2006)
- Fourth Circuit (1999)
- Fifth Circuit (1999)
Publications:
- “SEC Enforcement Actions and Investigations in Private and Public Offerings,” Securities: Public and Private Offerings, Second Edition, West Publishing 2007
- “Dura Pharmaceuticals: Loss Causation Redefined or Merely Clarified?” J.Tax’n & Reg. Fin. Inst. September/October 2007, Page 5